• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M.

作者信息

Gurnari Carmelo, Gagelmann Nico, Badbaran Anita, Awada Hussein, Dima Danai, Pagliuca Simona, D'Aveni-Piney Maud, Attardi Enrico, Voso Maria Teresa, Cerretti Raffaella, Wolschke Christine, Rubio Marie Thérèse, Maciejewski Jaroslaw P, Kröger Nicolaus

机构信息

Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.

出版信息

Leukemia. 2023 Mar;37(3):717-719. doi: 10.1038/s41375-023-01820-4. Epub 2023 Jan 28.

DOI:10.1038/s41375-023-01820-4
PMID:36709353
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11104020/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a622/11104020/e43bfa072e20/nihms-1962633-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a622/11104020/e43bfa072e20/nihms-1962633-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a622/11104020/e43bfa072e20/nihms-1962633-f0001.jpg

相似文献

1
Outcome prediction in myelodysplastic neoplasm undergoing hematopoietic cell transplant in the molecular era of IPSS-M.国际预后评分系统修订版（IPSS-M）分子时代下接受造血细胞移植的骨髓增生异常综合征的预后预测
Leukemia. 2023 Mar;37(3):717-719. doi: 10.1038/s41375-023-01820-4. Epub 2023 Jan 28.
2
Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.改良国际预后评分系统（IPSS-R）在前次异基因造血干细胞移植后并不能改善骨髓增生异常综合征患者的移植后结局：单中心经验。
Biol Blood Marrow Transplant. 2018 Jun;24(6):1209-1215. doi: 10.1016/j.bbmt.2018.02.007. Epub 2018 Feb 20.
3
[The prognostic significance of pretransplantation evaluation of IPSS-R and WPSS in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic stem cell transplantation].[国际预后评分系统修订版（IPSS-R）和世界卫生组织预后评分系统（WPSS）在接受异基因造血干细胞移植的骨髓增生异常综合征患者中的移植前评估的预后意义]
Zhonghua Xue Ye Xue Za Zhi. 2022 Mar 14;43(3):247-254. doi: 10.3760/cma.j.issn.0253-2727.2022.03.011.
4
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party.在接受异基因造血干细胞移植的骨髓增生异常综合征/转化急性髓系白血病患者中验证修订后的 IPSS 在移植时的准确性：EBMT 慢性恶性肿瘤工作组的回顾性分析。
Bone Marrow Transplant. 2017 Nov;52(11):1519-1525. doi: 10.1038/bmt.2017.171. Epub 2017 Sep 11.
5
Combining gene variants with clinical characteristics improves outcome prediction in Chinese patients with myelodysplastic syndromes.将基因变异与临床特征相结合可提高中国骨髓增生异常综合征患者的预后预测。
Leuk Lymphoma. 2020 Apr;61(4):919-926. doi: 10.1080/10428194.2019.1702177. Epub 2019 Dec 16.
6
Components of the revised International Prognostic Scoring System and outcome after hematopoietic cell transplantation for myelodysplastic syndrome.修订后的国际预后评分系统的组成部分及骨髓增生异常综合征造血细胞移植后的结局
Blood. 2013 May 9;121(19):4007-8. doi: 10.1182/blood-2013-02-486118.
7
Comparison of the prognostic predictive value of Molecular International Prognostic Scoring System and Revised International Prognostic Scoring System in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms.分子国际预后评分系统与修订的国际预后评分系统对接受异基因造血干细胞移植治疗骨髓增生异常综合征患者的预后预测价值比较
Am J Hematol. 2023 Dec;98(12):E391-E394. doi: 10.1002/ajh.27099. Epub 2023 Sep 20.
8
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity.异基因造血细胞移植治疗骨髓增生异常综合征：移植前 IPSS 评分和合并症的预后意义。
Bone Marrow Transplant. 2010 Mar;45(3):450-7. doi: 10.1038/bmt.2009.190. Epub 2009 Aug 10.
9
Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT.主要采用高剂量异基因造血干细胞移植治疗的骨髓增生异常综合征移植前预后因素：欧洲血液与骨髓移植协作组（EBMT）CMWP的MDS小组委员会的一项回顾性研究
Ann Hematol. 2016 Dec;95(12):1971-1978. doi: 10.1007/s00277-016-2802-z. Epub 2016 Sep 20.
10
Selection of Patients With Myelodysplastic Syndrome for Allogeneic Hematopoietic Stem Cell Transplantation.骨髓增生异常综合征患者异基因造血干细胞移植的选择
Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S49-52. doi: 10.1016/j.clml.2016.02.023.

引用本文的文献

1
Conditioning intensity in myelodysplastic patients aged ≥ 50 years undergoing allogeneic hematopoietic cell transplantation (allo-HCT): a study on behalf of the chronic malignancies working party of the EBMT.年龄≥50岁的接受异基因造血细胞移植（allo-HCT）的骨髓增生异常综合征患者的预处理强度：一项代表欧洲血液与骨髓移植协会慢性恶性肿瘤工作组开展的研究
Bone Marrow Transplant. 2025 Aug 29. doi: 10.1038/s41409-025-02682-3.
2
Advances and Challenges in the Management of Myelodysplastic Syndromes.骨髓增生异常综合征治疗的进展与挑战
Cancers (Basel). 2025 Jul 25;17(15):2469. doi: 10.3390/cancers17152469.
3
Allogeneic Transplant for CMML.

本文引用的文献

1
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.骨髓增生异常综合征的分子国际预后评分系统
NEJM Evid. 2022 Jul;1(7):EVIDoa2200008. doi: 10.1056/EVIDoa2200008. Epub 2022 Jun 12.
2
Clinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria.再生障碍性贫血和阵发性睡眠性血红蛋白尿症中克隆进化的临床和分子决定因素。
J Clin Oncol. 2023 Jan 1;41(1):132-142. doi: 10.1200/JCO.22.00710. Epub 2022 Sep 2.
3
Have we reached a molecular era in myelodysplastic syndromes?
慢性粒单核细胞白血病的异基因移植
Curr Hematol Malig Rep. 2025 Aug 11;20(1):10. doi: 10.1007/s11899-025-00754-1.
4
IPSS-M outperforms IPSS-R in prognostic stratification and guides effective interventions for very High-Risk myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation.国际预后评分系统-骨髓（IPSS-M）在预后分层方面优于国际预后评分系统-修订版（IPSS-R），并为接受异基因造血干细胞移植的极高危骨髓增生异常综合征患者指导有效的干预措施。
Discov Oncol. 2025 Jul 11;16(1):1315. doi: 10.1007/s12672-025-03155-1.
5
Threefold IPSS-M reclassification outperforms original stratification in predicting post-transplant outcomes for MDS patients.在预测骨髓增生异常综合征（MDS）患者移植后结局方面，IPSS-M三分法重新分类优于原始分层。
Cell Transplant. 2025 Jan-Dec;34:9636897251348406. doi: 10.1177/09636897251348406. Epub 2025 Jun 24.
6
Advances and challenges in the treatment of myelodysplastic syndromes.骨髓增生异常综合征治疗的进展与挑战
Exp Hematol Oncol. 2025 Jun 18;14(1):87. doi: 10.1186/s40164-025-00678-9.
7
Allogeneic Stem Cell Transplant for Myelofibrosis and Myelodysplastic Syndromes: A Contemporary Review.异基因干细胞移植治疗骨髓纤维化和骨髓增生异常综合征：当代综述
Am J Hematol. 2025 Jun;100 Suppl 4(Suppl 4):16-29. doi: 10.1002/ajh.27660. Epub 2025 Mar 13.
8
Validation and improvement of the molecular international prognostic scoring system in Chinese patients with myelodysplastic syndromes.分子国际预后评分系统在中国骨髓增生异常综合征患者中的验证与改进
Ann Hematol. 2025 Jan;104(1):193-206. doi: 10.1007/s00277-024-06162-4. Epub 2024 Dec 30.
9
Treatment of high-risk myelodysplastic syndromes.高危骨髓增生异常综合征的治疗
Haematologica. 2025 Feb 1;110(2):339-349. doi: 10.3324/haematol.2023.284946.
10
Allogeneic hematopoietic cell transplantation in elderly patients with myelodysplastic syndromes: Considerations and challenges.老年骨髓增生异常综合征患者的异基因造血细胞移植：考量与挑战
Semin Hematol. 2024 Dec;61(6):420-430. doi: 10.1053/j.seminhematol.2024.10.004. Epub 2024 Oct 17.
我们是否已经进入骨髓增生异常综合征的分子时代？
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):418-427. doi: 10.1182/hematology.2021000276.
4
'We cannot paint them all with the same brush': the need for a better definition of patients with myelodysplastic syndromes for clinical trial design.“我们不能一概而论”：为临床试验设计更好地定义骨髓增生异常综合征患者的必要性。
Br J Haematol. 2022 Jan;196(2):268-269. doi: 10.1111/bjh.17909. Epub 2021 Oct 24.
5
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.骨髓增生异常综合征：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2021 Feb;32(2):142-156. doi: 10.1016/j.annonc.2020.11.002. Epub 2020 Nov 19.
6
Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.年龄和造血细胞移植特异性合并症指数在接受异体移植的骨髓增生异常患者中的作用：来自欧洲血液和骨髓移植学会慢性恶性肿瘤工作组的回顾性研究。
Biol Blood Marrow Transplant. 2020 Mar;26(3):451-457. doi: 10.1016/j.bbmt.2019.10.015. Epub 2019 Oct 21.
7
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.异基因造血干细胞移植后骨髓增生异常综合征的改良 EBMT 移植特异性风险评分。
Haematologica. 2019 May;104(5):929-936. doi: 10.3324/haematol.2018.200808. Epub 2019 Jan 17.
8
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.骨髓增生异常综合征和继发性急性髓系白血病中的基因异常：对干细胞移植结果的影响。
Blood. 2017 Apr 27;129(17):2347-2358. doi: 10.1182/blood-2016-12-754796. Epub 2017 Feb 21.
9
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.干细胞移植后骨髓增生异常综合征的预后性突变
N Engl J Med. 2017 Feb 9;376(6):536-547. doi: 10.1056/NEJMoa1611604.
10
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.异基因造血干细胞移植治疗骨髓增生异常综合征和慢性粒-单核细胞白血病：国际专家小组的建议
Blood. 2017 Mar 30;129(13):1753-1762. doi: 10.1182/blood-2016-06-724500. Epub 2017 Jan 17.